Bioengineered Protein Drugs Market to reach USD 532.27 billion by 2030, Driven by Rising Biologic Adoption and Expanding Therapeutic Use

Mordor Intelligence has published a new report on bioengineered protein drugs market offering a comprehensive analysis of trends, growth drivers, and future projection

Introduction

The bioengineered protein drugs market is gaining steady attention as biologic therapies become central to modern disease management. According to Mordor Intelligence, The bioengineered protein drugs market size stood at USD 372.18 billion in 2025 and is forecast to reach USD 532.27 billion by 2030, advancing at a 7.42% CAGR, reflecting strong demand across chronic, genetic, and immune-related conditions. These therapies, which include insulin, monoclonal antibodies, growth factors, and enzyme-based drugs, are developed using recombinant DNA and protein engineering techniques to closely mimic or enhance naturally occurring proteins in the human body.

The increasing burden of long-term illnesses, coupled with a growing preference for targeted therapies, continues to support the expansion of the bioengineered protein drugs market growth. Healthcare systems are also showing higher acceptance of biologics due to their proven effectiveness, predictable safety profiles, and expanding regulatory approvals across major regions.

Report Overview:

https://www.mordorintelligence.com/industry-reports/bioengineered-protein-drugs-market?utm_source=openpr

Key Trends

Rising Preference for Biologic Therapies
Protein-based drugs are increasingly favored in oncology, autoimmune, and metabolic disease treatment due to their targeted action on specific biological pathways, strengthening the market share of biologics over traditional small-molecule drugs.

Expansion of Biosimilars Adoption
The expiration of patents for major biologics is enabling biosimilars to enter the market, improving affordability and access while supporting volume-driven growth, especially in emerging healthcare systems.

Advances in Manufacturing Efficiency
Developers are optimizing production processes to enhance yield consistency, protein stability, and scalability, helping manufacturers meet growing global demand more reliably.

Strategic Industry Collaborations
Partnerships between biotechnology companies and pharmaceutical manufacturers are accelerating development timelines and improving commercialization efficiency while maintaining regulatory compliance.

Market Segmentation

The bioengineered protein drugs market analysis highlights a structured segmentation based on product type, application, and distribution channel, reflecting the diverse use cases of protein-based therapies.

By Product Type

Monoclonal Antibodies

Hormones (e.g., Insulin, GLP-1)

Cytokines & Interleukins

Coagulation Factors

Enzymes

Fusion Proteins

Protein-subunit Vaccines

Others

By Expression System

Mammalian Cell Culture (CHO, HEK293, NS0, BHK)

Microbial Fermentation (E. coli, Yeast)

Plant-based Systems

Insect Cell Systems

By Disease Indication

Oncology

Diabetes & Metabolic Disorders

Autoimmune & Inflammatory Diseases

Cardiovascular Diseases

Infectious Diseases

Genetic Disorders

Others

By Route of Administration

Parenteral

Oral

Inhalation

Transdermal

By End User

Hospitals

Specialty Clinics

Homecare Settings

Research & Academic Institutes

By Geography

North America

South Amerca

Middle east&Africa

Europe

Asia pacific

This segmentation structure supports stable bioengineered protein drugs market growth across both developed and developing healthcare systems.

Key Players

The bioengineered protein drugs market is characterized by the presence of global pharmaceutical companies and specialized biotechnology firms with strong research pipelines. Leading players continue to invest in biologic drug portfolios, focusing on therapeutic expansion, lifecycle management, and geographic reach.

F. Hoffmann-La Roche Ltd

AbbVie

Merck & Co.

Novo Nordisk

Johnson & Johnson

Continuous engagement with regulatory authorities and adherence to established manufacturing standards remain essential strategies for companies aiming to sustain long-term presence in the market.

Conclusion

The outlook for the bioengineered protein drugs market growth remains positive as biologics continue to play a critical role in modern healthcare. Rising disease prevalence, increased clinical reliance on targeted therapies, and broader patient access through biosimilars are reinforcing long-term demand. Healthcare providers and payers are recognizing the value of protein-based drugs in improving treatment outcomes, supporting their integration into standard care pathways.

As highlighted in this bioengineered protein drugs market analysis, the market's structured segmentation, competitive yet stable landscape, and strong therapeutic relevance position it for sustained expansion over the forecast period. With ongoing focus on quality, safety, and accessibility, the market is expected to maintain its importance within the global pharmaceutical industry while meeting evolving patient and healthcare system needs.


For complete market analysis, please visit the Mordor Intelligence page:

https://www.mordorintelligence.com/industry-reports/bioengineered-protein-drugs-market?utm_source=openpr

Industry related Reports:

Peptide Antibiotics Market : The Peptide Antibiotics Market is Segmented by Product Type (Ribosomal-Synthesised and Non-Ribosomal-Synthesised), Disease (Skin Infections, HABP/VABP, and More), Route of Administration (Injectable, Topical, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, and More).

Get more Insights: https://www.mordorintelligence.com/industry-reports/peptide-antibiotics-market?utm_source=openpr

Peptide Drug Conjugates Market: The Peptide Drug Conjugates Market is Segmented by Type (Therapeutic and Diagnostic), Disease (Gastroenteropancreatic Neuroendocrine Tumors, Multiple Myeloma, and Other Diseases), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

Get more Insights: https://www.mordorintelligence.com/industry-reports/peptide-drug-conjugates-market?utm_source=openpr

Protein-Based Cancer Therapeutics Market: The Protein-Based Cancer Therapeutics Market report segments the industry into By Product Type (Monoclonal Antibodies, Hormones, Fusion Proteins, Others), By Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Other Cancer Types), By End User (Hospitals, Ambulatory Surgical Centers, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, South America).

Get more Insights: https://www.mordorintelligence.com/industry-reports/protein-based-cancer-therapeutics-market?utm_source=openpr



About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

This release was published on openPR.